SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 1

Metformin, myo-inositol and D-chiro-inositol use and ART outcomes in women with PCOS: current results and future perspectives

Metformin, myoinositol ve D-chiro kullanımı ve PCOS art sonuçları

Cemil Kaya0000-0001-6764-4714
Pages
—
Publication Date
2026-01-05
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, metabolic, hormonal and reproductive results are collected holistically.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polycystic ovary syndrome (PCOS) remains the most common endocrine disorder in women worldwide.
📊
Key Findings & Data:PCOS affects 5-18% of women, and is a reproductive, metabolic, and psychological condition.
💡
Conclusion & Impact:In this review, metabolic, hormonal and reproductive results are collected holistically.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:PCOS · inositol · metformin

Abstract

Polycystic ovary syndrome (PCOS) remains the most common endocrine disorder in women worldwide. PCOS affects 5-18% of women, and is a reproductive, metabolic, and psychological condition. Oligomenorrhea, obesity, infertility, hyperandrogenemia and insulin resistance (IR) constitute the common features of PCOS. IR has a critical role in the pathogenesis of PCOS. Metabolic abnormalities in PCOS patients are manifested by IR, dysregulation of glucose metabolism, lipid metabolism disorders. The primary defect in IR in PCOS is the postreceptor defect. The association between hyperinsulinemia, hyperandrogenism, and ovulatory dysfunction in PCOS formed a basis for treatment with insulin-sensitizing agents such as inositol derivatives and metformin. Reducing IR in these patients has a positive effect on both metabolic and reproductive outcomes. Current data support the notion that inositol isoforms myo-inositol (MYO), D-chiro inositol (DCI) and metformin may be effective in the treatment of patients with PCOS. In combination with MYO and DCI, it has metabolic and hormonal effects similar to those of merformin in PCOS. In terms of in vitro fertilization/İntractoplasmic sperm injenction (IVF/ICSI) IVF results, both MYO and MYO plus DCI use have positive effects on ovarian response. However, the effects on clinical pregnancy rate (CPR) and live birth rates (LBR) appear to be limited. As a supplement, preventive strategies and IVF results of these treatments are presented and discussed in detail. The controversial aspect of the issue begins at this point and future perspective approaches are presented along with current results. In this review, metabolic, hormonal and reproductive results are collected holistically.

Özet

Polikistik over sendromu (PKOS), dünya çapında kadınlarda en sık görülen endokrin bozukluk olmaya devam etmektedir. PKOS, kadınların %5-18'ini etkileyen üreme sistemiyle birlikte, metabolik ve psikolojik komponentleri olan bir kondisyondur. İnsülin direnci (İD), PKOS patogenezinde kritik bir role sahiptir. PKOS hastalarındaki metabolik anormallikler İD, glikoz metabolizması ve lipid metabolizması bozuklukları ile kendini göstermektedir. PKOS'ta İD'deki birincil defekt postreseptör defektidir. PKOS'ta hiperinsülinemi, hiperandrojenizm ve yumurtlama disfonksiyonu arasındaki ilişki, inositol türevleri ve metformin gibi insülin duyarlılaştırıcı ajanlarla tedavi için bir temel oluşturmuştur. Bu hastalarda insülin direncinin azaltılması hem metabolik hem de üreme sonuçları üzerinde olumlu bir etkiye sahiptir. Güncel veriler inositol izoformlarının (myo inositol ve D-chiro) ve metforminin PKOS'lu hastaların tedavisinde etkili olabileceği görüşünü desteklemektedir. Bu derlemede bir tamamlayıcı olarak, bu tedavilerin önleyici stratejileri ve IVF sonuçları sunulmuş ve ayrıntılı olarak tartışılmıştır. Miyo inositol ve d-chiro ile kombinasyon halinde polikistik over sendromunda merformine benzer metabolik ve hormonal etkiler ortaya çıkarmaktadır. IVF sonuçları açısından, hem myoinositol hem de myoinositol artı d-chiro kullanımının over yanıtı üzerinde olumlu etkileri olmasına rağmen, meta-analiz sonuçlarına göre bu henüz gebelik ve canlı doğum oranlarına yansımamıştır. Konunun tartışmalı yönü bu noktada başlamakta ve geleceğe yönelik perspektif yaklaşımları güncel sonuçlarla birlikte sunulmaktadır. Bu derlemede metabolik, hormonal ve üremeye ilişkin sonuçlar bütünsel olarak toplanmıştır.

🔖

Cite This Article

Kaya, C. (2026). Metformin, myo-inositol and D-chiro-inositol use and ART outcomes in women with PCOS: current results and future perspectives. Journal of Health Sciences and Medicine, Volume: 9 Issue: 1. https://doi.org/10.32322/jhsm.1803630

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (50)

  1. Johnson T, Kaplan L, Ouyang P, Rizza R. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS). NIH EbMW Report. Bethesda, National Institutes of Health. 2012;1:1-14.
  2. Roseff S, Montenegro M. Inositol treatment for PCOS should be science-based and not arbitrary. Int J Endocrinol. 2020;2020:6461254. doi:10.1155/2020/6461254
  3. Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12(12):CD 006105. doi:10.1002/14651858.CD006105.pub4
  4. Tabatabaie M, Amiri S, Golestan Jahromi M. The effect of myo-inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndrome. Molecular Biology Reports. 2022;49:875-884. doi:10.1007/s11033-021-06833-9
  5. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288:1405-1411. doi:10.1007/s00404-013-2855-3
  6. Gateva A, Unfer V, Kamenov Z. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. Gynecol Endocrinol. 2018; 34(7):545-550. doi:10.1080/09513590.2017.142 1632
  7. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015;31(2):131-135. doi:10.3109/09513590.2014.964640
  8. Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol. 2016;2016:1849162. doi:10.1155/2016/ 1849162
  9. Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. a randomized study. Gynecol Endocrinol. 2013;29(4):375-379. doi:10.3109/ 09513590.2012.743020
  10. Papaleo E, Unfer V, Baillargeon J-P, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility. 2009;91(5):1750-1754. doi:10.1016/j.fertnstert.2008.01.088
  11. Pundir J, Psaroudakis D, Savnur P, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299-308. doi:10.1111/1471-0528. 14754
  12. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine. 1999;340(17):1314-1320. doi:10.1056/nejm199904293401703
  13. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417-423. doi:10.4158/EP.8.6.417
  14. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7(6):151-159.
  15. Unfer V. Facchinetti F. Orrù B. Giordani B. Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections. 2017;6(8):647-658. doi:10.1530/ec-17-0243
  16. Isabella R, Raffone E. Concern: Does ovary need d-chiro-inositol?. J Ovarian Res. 2012;5(1):14. doi:10.1186/1757-2215-5-14
  17. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288(6):1405-1411. doi:10.1007/s00404-013-2855-3
  18. Nordio M, Proietti E. The combined therapy with myo-inositol and d-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575-581.
  19. Rajasekaran K, Malhotra N, Mahey R, Khadgawat R, Kalaivani M. Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study. Gynecol Endocrinol. 2022;38(2):140-147. doi:10.1080/09513590.2021.1981282
  20. Unanyan A, Pivazyan L, Krylova E, et al. Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis. Gynecol Endocrinol. 2022;38(12):1035-1046. doi:10.1080/09513590.2022.2136160
  21. Prabhakar P, Mahey R, Gupta M, et al. Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles-randomized controlled trial. Gynecol Endocrinol. 2021;37(4):332-336. doi:10.1080/09513590.2020.1810657
  22. Mendoza N, Diaz-Ropero MP, Aragon M, et al. Comparison of the effect of two combinations of myo-inositol and d-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695-700. doi:10.1080/09513590.2019.1576620
  23. Emekçi Özay Ö, Özay AC, Çağlıyan E, Okyay RE, Gülekli B. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecol Endocrinol. 2017;33 (7):524-528. doi:10.1080/09513590.2017.1296127
  24. Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D'Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298(4):675-684. doi:10.1007/s00404-018-4861-y
  25. Regidor PA, Schindler AE, Lesoine B, Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig. 2018;34(2):/j/hmbci.2018.34.issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. doi:10. 1515/hmbci-2017-0067
  26. Sene AA, Tabatabaie A, Nikniaz H, et al. The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Arch Gynecol Obstet. 2019;299:1701-7. doi:10. 1007/s00404-019-05111-1
  27. Merviel P, James P, Bouée S, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021;18(1):13. doi:10.1186/s12978-021-01073-3
  28. Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A.Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2016;32(1):69-73. doi:10.3109/09513590.2015.1101444
  29. Artini PG, Simi G, Ruggiero M, et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol Endocrinol. 2012;28(9):669-673. doi:10.3109/09513590.2012.705386
  30. Zheng X, Lin D, Zhang Y, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017;96(49):e8842. doi:10.1097/MD.0000000000008842
  31. Zhang J, Zhang H, Zhou W, Jiang M, Lin X. Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1520 362. doi:10.3389/fendo.2025.1520362
  32. Sene AA, Saeedzarandi M, Yazdizadeh M, et al. The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trial studies. Int J Reprod Biomed. 2025;23(5):353-376. doi:10.18502/ijrm.v23i5.19260
  33. Bhide P, Pundir J, Gudi A, Shah A, Homburg R, Acharya G.The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019;98(10):1235-1244. doi:10.1111/aogs.13625
  34. Mendoza N, Pérez L, Simoncini T, Genazzani A. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017;35(5):529-535. doi:10.1016/j.rbmo.2017.07.005
  35. Aragona C, Russo M, Myers SH, Espinola MSB, Bilotta G, Unfer V. A retrospective study "myo-inositol is a cost-saving strategy for controlled ovarian stimulation in non-polycystic ovary syndrome art patients.". Health Econ Rev. 2025;15(1):20. doi:10.1186/s13561-025-00609-8
  36. Vartanyan EV, Tsaturova KA, Devyatova EA, et al. Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization. Gynecol Endocrinol. 2017;33(sup1):8-11. doi:10.1080/09513590.2017.1399699
  37. Artini PG, Malacarne E, Tomatis V, Genazzani AD. The relevance of inositols treatment for PCOS before and during ART. Eur Rev Med Pharmacol Sci. 2021;25(14):4799-4809. doi:10.26355/eurrev_202107_ 26393
  38. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;12(12):CD012378. doi:10.1002/14651858.CD012 378.pub2
  39. Seyedoshohadaei F, Abbasi S, Rezaie M, et al. Myo-inositol effect on pregnancy outcomes in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: a double-blind RCT. Int J Reprod Biomed. 2022;20(8):643-650. doi:10.18502/ijrm.v20i8.11753
  40. Mohammadi S, Eini F, Bazarganipour F, Taghavi SA, Kutenaee MA. The effect of myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. Reprod Biol Endocrinol. 2021;19(1):61. doi:10.1186/s12958-021-00741-0
  41. Azizi Kutenaei M, Hosseini Teshnizi S, Ghaemmaghami P, Eini F, Roozbeh N. The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(7):3105-3115. doi: 10.26355/eurrev_202104_25565
  42. Greff D, Juhász AE, Váncsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023; 21(1):10. doi:10.1186/s12958-023-01055-z
  43. Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;59(1): 30-38. doi:10.1007/s12020-017-1442-y
  44. Fitz V, Graca S, Mahalingaiah S, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. J Clin Endocrinol Metab. 2024;109(6):1630-1655. doi:10.1210/clinem/dgad762
  45. Gupta D, Khan S, Islam M, Malik BH, Rutkofsky IH. Myo-inositol's role in assisted reproductive technology: evidence for improving the quality of oocytes and embryos in patients with polycystic ovary syndrome. Cureus. 2020;12(5):e8079. doi:10.7759/cureus.8079
  46. Unfer V, Russo M, Aragona C, Bilotta G, Montanino Oliva M, Bizzarri M. Treatment with myo-inositol does not improve the clinical features in all PCOS phenotypes. Biomedicines. 2023;11(6):1759. doi:10. 3390/biomedicines11061759
  47. Palomba S, Viganò P, Chamayou S, et al. Diagnosis and management of infertility: NICE-adapted guidelines from the Italian Society of Human Reproduction. Reprod Biol Endocrinol. 2024;22(1):9. doi:10.1186/s12958- 023-01179-2
  48. Wdowiak A, Bakalczuk S, Filip M, Laganà AS, Unfer V. The clinical use of myo-inositol in ivf-et: a position statement from the experts group on inositol in basic and clinical research and on PCOS (EGOI-PCOS), the polish society of andrology, and the international scientific association for the support and development of medical technologies. J Clin Med. 2025;14(2):558. doi:10.3390/jcm14020558
  49. Moretti C, Bonomi M, Dionese P, et al. Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology. J Endocrinol Invest. 2024;47(9):2111-2141. doi:10.1007/s40618-024-02363-w
  50. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288:1405-1411. doi:10.1007/s00404-013-2855-3